.Attribute Medication, Published online: 30 July 2024 doi:10.1038/ d41591-024-00054-wThe antibody-- medicine conjugate (ADC) tisotumab vedotin resulted in enhanced progression-free and also general survival, causing FDA approval as well as a new therapy possibility for people.